quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·32d
PRRelease
Insmed Incorporated logo

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

INSM· Insmed Incorporated
Health Care
Original source

Companies

  • INSM
    Insmed Incorporated
    Health Care

Recent analyst ratings

  • Apr 10UpdateRaymond James$200.00
  • Mar 30UpdateMorgan Stanley$212.00
  • Mar 16UpdateJefferies-
  • Jan 28UpdateBarclays$231.00
  • Jan 23UpdateRoth Capital$212.00
  • Dec 19UpdateTruist$202.00

Related

  • PR1d
    Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
  • INSIDER6d
    SEC Form 4 filed by Lewis William
  • ANALYST14d
    Raymond James initiated coverage on Insmed with a new price target
  • INSIDER15d
    SEC Form 4 filed by Lewis William
  • SEC16d
    Insmed Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR16d
    Insmed Provides Clinical Update on Phase 2b CEDAR Study
  • INSIDER20d
    SEC Form 4 filed by Adsett Roger
  • SEC22d
    SEC Form DEFA14A filed by Insmed Incorporated
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022